首页> 外文期刊>Analytical chemistry >Laser-Induced Liquid Bead Ion Desorption Mass Spectrometry: An Approach to Precisely Monitor the Oligomerization of the beta-Amyloid Peptide
【24h】

Laser-Induced Liquid Bead Ion Desorption Mass Spectrometry: An Approach to Precisely Monitor the Oligomerization of the beta-Amyloid Peptide

机译:激光诱导的液珠离子解吸质谱:一种精确监控β-淀粉样肽寡聚化的方法

获取原文
获取原文并翻译 | 示例
       

摘要

In the present work, the recently developed laser-induced liquid bead ion desorption mass spectrometry (LILBID MS) is applied as a novel technique to study A(beta) oligomerization, thought to be crucial in Alzheimer's disease (AD). The characterization of the earliest nucleation events of this peptide necessitates the application of several techniques to bridge the gap between small oligomers and large fibrils. We precisely monitored in time the transformation of monomeric A(beta) (1-42) into oligomeric A(beta)_(n) (n < 20) and its dependence on concentration and agitation. The distribution shows signs of the hexamer being crucial in the assembly process. The intensity of the monomer decreases in time with a time constant of about 9 h. After a lag time of around 10 h, a phase transition occurred in which the total ion current of the oligomers goes to nearly zero. In this late stage of aggregation, protofibrils are formed and mass spectrometry is no longer sensitive. Here fluorescence correlation spectroscopy (FCS) and transmission electron microscopy (TEM) are complementary tools for detection and size characterization of these large species. We also utilized the oligomers of A(beta) (1-42) as a model of the corresponding in vivo process to screen the efficacy and specificity of small molecule inhibitors of oligomerization. The LILBID results are in excellent agreement with condensed phase behavior determined in other studies. Our data identified LILBID MS as a powerful technique that will advance the understanding of peptide oligomerization in neurodegenerative diseases and represents a powerful tool for the identification of small oligomerization inhibitors.
机译:在本工作中,最近开发的激光诱导液珠离子解吸质谱法(LILBID MS)被用作研究Aβ低聚的一种新技术,Aβ低聚被认为对阿尔茨海默病(AD)至关重要。该肽的最早成核事件的表征需要应用几种技术来弥合小寡聚物和大原纤维之间的缺口。我们精确地及时监测了单体Aβ(1-42)向寡聚Aβ_(n)(n <20)的转化及其对浓度和搅拌的依赖性。该分布表明六聚体在组装过程中至关重要。单体的强度随时间常数约9小时随时间减小。在大约10 h的滞后时间后,发生了相变,其中低聚物的总离子电流接近于零。在聚集的后期,原纤维形成,质谱不再敏感。在这里,荧光相关光谱(FCS)和透射电子显微镜(TEM)是用于检测和鉴定这些大物种的互补工具。我们还利用Aβ(1-42)的低聚物作为相应的体内过程的模型来筛选低聚小分子抑制剂的功效和特异性。 LILBID结果与其他研究确定的凝结相行为非常吻合。我们的数据将LILBID MS鉴定为一种有力的技术,它将促进对神经退行性疾病中肽寡聚化的理解,并且是鉴定小型寡聚化抑制剂的有力工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号